Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer-Reference-Cited by-同舟云学术

Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Published:2021 Issue:2 Volume:9 Page:443-455
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Yang Lili¹²³⁴⁵,Liu Shanshan¹²³⁴⁵,Chu Jingjing¹²³⁴⁵,Miao Shuang¹²³⁴⁵,Wang Kai¹²³⁴⁵,Zhang Qingwei¹²³⁴⁵,Wang Yingyi¹²³⁴⁵,Xiao Yadi¹²³⁴⁵,Wu Lina¹²³⁴⁵,Liu Yang¹²³⁴⁵,Yu Longjian¹²³⁴⁵,Yu Caihong¹²³⁴⁵,Liu Xiang¹²³⁴⁵,Ke Mingxing¹²³⁴⁵,Cheng Zhen⁶⁷⁸⁹¹⁰^ORCID,Sun Xilin¹²³⁴⁵^ORCID

Affiliation:

1. NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics

2. Molecular Imaging Research Center (MIRC)

3. Harbin Medical University

4. Harbin

5. China

6. Molecular Imaging Program at Stanford (MIPS)

7. Department of Radiology

8. Stanford University School of Medicine

9. Stanford

10. USA

Abstract

The two novel anilino quinazoline-based EGFR-TKIs have promising anti-tumor activity and limited hepatotoxicity, representing excellent candidates for combating the NSCLC.

Funder

National Natural Science Foundation of China

National Basic Research Program of China

Natural Science Foundation of Heilongjiang Province

Harbin Science and Technology Bureau

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2021/BM/D0BM00293C

Reference34 articles.